NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma

Glioblastoma (GBM) is a type of central nervous system malignancy. In our study, we determined the effect of in GBM patients through The Cancer Genome Atlas (TCGA) data analysis, and studied the effects of on GBM cell function to estimate its potential as a therapeutic target. Gene expression profiles of glioblastoma cohort were acquired from TCGA database and analyzed to look for central genes that may serve as GBM therapeutic targets. Then the cell function of in glioblastoma cell was explored through in vitro cell experiments. Through gene ontology (GO) analysis, weighted gene co-expression network analysis (WGCNA), and survival analysis, we identified three key genes ( , and ) associated with poor prognosis in glioblastoma. In vitro experiments showed impaired cell migration, apoptosis, and cell cycle arrest in knockdown cells. affects the progress and prognosis of glioblastoma by promoting cell migration and inhibiting apoptosis.